Explore the vast range of titles available.

Several international non-governmental organizations (INGOs) function as boundary organizations and try to promote ecosystem-based adaptation (EbA) as a pivotal climate change adaptation strategy for coastal areas. This is being done in Vietnam. Few studies, however, have investigated how these INGOs operate, what challenges they face, and what conditions support them to successfully promote the implementation of EbA. To address this knowledge gap, the literature on international boundary work and boundary organizations was first reviewed, deriving four categories of conditions for a successful promotion of EbA: knowledge, networks, resources, and context. Next, we applied this framework in a case study of the International Union for Conservation (IUCN) and the Foundation of Netherlands Volunteers (SNV) led EbA project on the restoration and sustainable use of mangroves in two provinces, Ca Mau and Ben Tre, which are located in the Vietnamese Mekong Delta. We interviewed 25 key informants representing INGOs, Vietnamese governmental agencies, farmers, scientists, and market parties. Our case study not only revealed how most literature-based success conditions were met but also found some additional conditions. We found that INGOs will have a greater chance of successfully promoting the implementation of the EbA in cases in which they can act as a knowledge broker, have a strong international network, can supply enough resources, and use context-specific strategies. A supportive context appeared to be essential.

Genome-scale metabolic models have proven useful for answering fundamental questions about metabolic capabilities of a variety of microorganisms, as well as informing their metabolic engineering. However, only a few models are available for oxygenic photosynthetic microorganisms, particularly in cyanobacteria in which photosynthetic and respiratory electron transport chains (ETC) share components. We addressed the complexity of cyanobacterial ETC by developing a genome-scale model for the diazotrophic cyanobacterium, Cyanothece sp. ATCC 51142. The resulting metabolic reconstruction, iCce806, consists of 806 genes associated with 667 metabolic reactions and includes a detailed representation of the ETC and a biomass equation based on experimental measurements. Both computational and experimental approaches were used to investigate light-driven metabolism in Cyanothece sp. ATCC 51142, with a particular focus on reductant production and partitioning within the ETC. The simulation results suggest that growth and metabolic flux distributions are substantially impacted by the relative amounts of light going into the individual photosystems. When growth is limited by the flux through photosystem I, terminal respiratory oxidases are predicted to be an important mechanism for removing excess reductant. Similarly, under photosystem II flux limitation, excess electron carriers must be removed via cyclic electron transport. Furthermore, in silico calculations were in good quantitative agreement with the measured growth rates whereas predictions of reaction usage were qualitatively consistent with protein and mRNA expression data, which we used to further improve the resolution of intracellular flux values.

Patients with cancer cachexia display a general resistance to immune checkpoint inhibitor (ICI) therapy, and baseline ICI catabolic clearance is a predictive indicator for overall survival, independent of dose and drug exposure. Fc-gamma (FcγRs) and neonatal Fc receptors (FcRn) play key roles in ICI clearance and efficacy, and we aimed to determine the impact of cachexia, independent of tumor, on immune cell populations and their Fc receptor (FcR) expression in patients and in murine models of cancer, cachexia, and cancer cachexia. Immune cell populations and their FcR expression were measured in tumor-bearing and tumor-free mice, with/without cachexia, and from patients with non-small cell lung cancer (NSCLC) and renal cell carcinoma. These measures, upon splenocytes and peripheral blood mononuclear cells (PBMCs) in mice and humans respectively, were compared with baseline ICI drug clearance and cachexia phenotype. Leukocyte populations and FcγR in mouse splenocytes displayed distinct expressional patterns when comparing across tumor and cachexia status. Univariate analyses revealed several correlations between FcγR expression on patient PBMCs and both ICI clearance and cachexia phenotype. Notably, FcRn expression was unchanged or slightly elevated in tumor-bearing mice and did not correlate with ICI clearance in murine splenocytes or patient leukocytes. Furthermore, immune cell populations and FcR expression were different among tumor types but did not differ in splenocytes of tumor-free mice with Activin A/IL-6 induced cachexia when compared with vector controls. These findings provide the first evidence that FcRs, critical for the efficacy and pharmacokinetics of many ICI and other IgG mAbs, are altered in a tumor-dependent manner. Furthermore, in the absence of a tumor, cachexia phenotype may not coincide with inflammation in the form of altered immune cell populations and elevated catabolic clearance of IgG mAbs, suggesting these features arise from properties intrinsic to the tumor.

Background/Objectives: In Vietnam, COVID-19 vaccination campaigns for children have encountered numerous challenges due to acceptance issues among parents. This study aimed to assess parental decision-making and identify factors influencing their decision to vaccinate their children against COVID-19. Methods: This was a cross-sectional online survey conducted between April and May 2023 among parents of children aged 6–17 years enrolled in urban and rural schools in Thai Nguyen province, Vietnam. Data on parental and child demographics, vaccination decision-making, COVID-19 experiences, and health beliefs based on the Health Belief Model were collected and analyzed, using univariate and multivariable multinomial regression analyses. Results: Among 4235 respondents (median age 41 years, 80.4% female), 81.3% had accepted all vaccine doses for their children, 9.7% had accepted some doses, 4.6% had rejected all doses, and 4.5% had not vaccinated their children for reasons unrelated to vaccine acceptance. Factors influencing parental decision-making included parental age, educational status, area of residence, health beliefs, prior experience with COVID-19 vaccination, and their child’s age and health status. Conclusions: We found overall high levels of parental acceptance for COVID-19 vaccination for children in Thai Nguyen province. To enhance COVID-19 vaccination acceptance, targeted communication strategies should focus on younger parents, those living in urban areas, parents with higher educational levels, and those with children who are younger or have underlying medical conditions. Trusted sources such as healthcare workers, teachers, and official health websites are essential for disseminating accurate information and fostering trust in vaccination programs.

New drugs targeting antimicrobial resistant pathogens, including , have been challenging to evaluate in clinical trials, particularly for the non-ventilated hospital-acquired pneumonia and ventilator-associated pneumonia indications. Development of new antibacterial drugs is facilitated by preclinical animal models that could predict clinical efficacy in patients with these infections. We report here an FDA-funded study to develop a rabbit model of non-ventilated pneumonia with by determining the extent to which the natural history of animal disease reproduced human pathophysiology and conducting validation studies to evaluate whether humanized dosing regimens of two antibiotics, meropenem and tobramycin, can halt or reverse disease progression. In a rabbit model of non-ventilated pneumonia, endobronchial challenge with live 6206, but not with UV-killed Pa6206, caused acute respiratory distress syndrome, as evidenced by acute lung inflammation, pulmonary edema, hemorrhage, severe hypoxemia, hyperlactatemia, neutropenia, thrombocytopenia, and hypoglycemia, which preceded respiratory failure and death. Pa6206 increased >100-fold in the lungs and then disseminated from there to infect distal organs, including spleen and kidneys. At 5 h post-infection, 67% of Pa6206-challenged rabbits had PaO <60 mmHg, corresponding to a clinical cut-off when oxygen therapy would be required. When administered at 5 h post-infection, humanized dosing regimens of tobramycin and meropenem reduced mortality to 17-33%, compared to 100% for saline-treated rabbits ( <0.001 by log-rank tests). For meropenem which exhibits time-dependent bactericidal activity, rabbits treated with a humanized meropenem dosing regimen of 80 mg/kg q2h for 24 h achieved 100% T>MIC, resulting in 75% microbiological clearance rate of Pa6206 from the lungs. For tobramycin which exhibits concentration-dependent killing, rabbits treated with a humanized tobramycin dosing regimen of 8 mg/kg q8h for 24 h achieved C /MIC of 9.8 ± 1.4 at 60 min post-dose, resulting in 50% lung microbiological clearance rate. In contrast, rabbits treated with a single tobramycin dose of 2.5 mg/kg had C /MIC of 7.8 ± 0.8 and 8% (1/12) microbiological clearance rate, indicating that this rabbit model can detect dose-response effects. The rabbit model may be used to help predict clinical efficacy of new antibacterial drugs for the treatment of non-ventilated pneumonia.

Basaloid squamous cell carcinoma is an infiltrative and aggressive variant of squamous cell carcinoma with basaloid features. Primary skin-derived basaloid squamous cell carcinoma is rare. Basaloid squamous cell carcinoma is commonly observed in the oropharyngeal and anogenital regions and is associated with high-risk human papillomavirus. We report a case of primary basaloid squamous cell carcinoma overlying the right scapula with metastasis to the regional lymph nodes and brain despite surgical resection and adjuvant chemoradiation. Histopathologic investigations of high-risk cutaneous squamous cell carcinoma do not routinely involve human papillomavirus testing. In contrast, oncogenic human papillomavirus and p16 are screened in head and neck squamous cell carcinoma for prognostication. Since the patient presented with an aggressive variant of squamous cell carcinoma and distal metastasis despite standard therapies, human papillomavirus testing was performed. P16, a surrogate marker for human papillomavirus infection and specifically HPV16 was identified in the tumor. This is a unique report of HPV16 in primary cutaneous basaloid squamous cell carcinoma with distal brain metastasis.

Here, we describe the clinical course of a patient with chronic obstructive pulmonary disease treated with autologous adipose‐derived stem cell therapy. In September 2019, our patient was admitted to Bach Mai Hospital. His post‐bronchodilator forced expiratory volume in 1 sec (FEV1) was 21% and FEV1/forced vital capacity (FVC) was 40%. He had suffered from two exacerbations of chronic obstructive pulmonary disease (COPD) in the previous year. He received treatment with autologous stem cells from adipose tissue. Follow‐up indicated that autologous stem cells from adipose tissue was a safe treatment and improved the patient's dyspnoea and quality of life. This study reports a case report of autologous adipose‐derived stem cells (ADSCs) treatment in a chronic obstructive pulmonary disease (COPD) patient. This treatment has been initially shown to be safe and partly effective. This finding has significant implications for clinical practice.

BackgroundMonoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are lacking. Recent ICI clinical pharmacology data demonstrate high baseline drug clearance (CL0) significantly associates with shorter overall survival, independent of ICI exposure, in patients receiving ICI mAb therapies. This suggests CL0 may predict outcomes from ICI therapy, and cachectic signalling may link elevated CL0 and poor response. Our aim was to determine if mouse models of cancer cachexia will be useful for studying these phenomena and their underlying mechanisms.MethodsWe evaluated pembrolizumab CL in the C26 and Lewis lung carcinoma mouse models of cancer cachexia. A single treatment of vehicle or pembrolizumab, at a dose of 2 or 10 mg/kg, was administered intravenously by tail vein injection. Pembrolizumab was quantified by an ELISA in serial plasma samples, and FcRn gene (Fcgrt) expression was assessed in liver using real‐time quantitative reverse transcription PCR. Non‐compartmental and mixed‐effects pharmacokinetics analyses were performed.ResultsWe observed higher pembrolizumab CL0 and decreased Fcgrt expression in whole liver tissue from tumour‐bearing vs. tumour‐free mice. In multivariate analysis, presence of tumour, total murine IgG, muscle weight and Fcgrt expression were significant covariates on CL, and total murine IgG was a significant covariate on V1 and Q.ConclusionsThese data demonstrate increases in catabolic clearance of monoclonal antibodies observed in humans can be replicated in cachectic mice, in which Fcgrt expression is also reduced. Notably, FcRn activity is essential for proper antigen presentation and antitumour immunity, which may permit the study of cachexia's impact on FcRn‐mediated clearance and efficacy of ICI therapies.

The neonatal Fc receptor (FcRn) is responsible for recycling of IgG antibodies and albumin throughout the body. This mechanism has been exploited for pharmaceutic delivery across an array of diseases to either enhance or diminish this function. Monoclonal antibodies and albumin-bound nanoparticles are examples of FcRn-dependent anti-cancer therapeutics. Despite its importance in drug delivery, little is known about FcRn expression in circulating immune cells. Through time-of-flight mass cytometry (CyTOF) we were able to characterize FcRn expression in peripheral blood mononuclear cell (PBMC) populations of pancreatic ductal adenocarcinoma (PDAC) patients and non-cancer donors. Furthermore, we were able to replicate these findings in an orthotopic murine model of PDAC. Altogether, we found that in both patients and mice with PDAC, FcRn was elevated in migratory and resident classical dendritic cell type 2 (cDC2) as well as monocytic and granulocytic myeloid-derived suppressor cell (MDSC) populations compared to tumor-free controls. Furthermore, PBMCs from PDAC patients had elevated monocyte, dendritic cells and MDSCs relative to non-cancer donor PBMCs. Future investigations into FcRn activity may further elucidate possible mechanisms of poor efficacy of antibody immunotherapies in patients with PDAC.

Background Shewanella is a genus of facultatively anaerobic, Gram-negative bacteria that have highly adaptable metabolism which allows them to thrive in diverse environments. This quality makes them an attractive bacterial target for research in bioremediation and microbial fuel cell applications. Constraint-based modeling is a useful tool for helping researchers gain insights into the metabolic capabilities of these bacteria. However, Shewanella oneidensis MR-1 is the only strain with a genome-scale metabolic model constructed out of 21 sequenced Shewanella strains. Results In this work, we updated the model for Shewanella oneidensis MR-1 and constructed metabolic models for three other strains, namely Shewanella sp. MR-4, Shewanella sp. W3-18-1, and Shewanella denitrificans OS217 which span the genus based on the number of genes lost in comparison to MR-1. We also constructed a Shewanella core model that contains the genes shared by all 21 sequenced strains and a few non-conserved genes associated with essential reactions. Model comparisons between the five constructed models were done at two levels – for wildtype strains under different growth conditions and for knockout mutants under the same growth condition. In the first level, growth/no-growth phenotypes were predicted by the models on various carbon sources and electron acceptors. Cluster analysis of these results revealed that the MR-1 model is most similar to the W3-18-1 model, followed by the MR-4 and OS217 models when considering predicted growth phenotypes. However, a cluster analysis done based on metabolic gene content revealed that the MR-4 and W3-18-1 models are the most similar, with the MR-1 and OS217 models being more distinct from these latter two strains. As a second level of comparison, we identified differences in reaction and gene content which give rise to different functional predictions of single and double gene knockout mutants using Comparison of Networks by Gene Alignment (CONGA). Here, we showed how CONGA can be used to find biomass, metabolic, and genetic differences between models. Conclusions We developed four strain-specific models and a general core model that can be used to do various in silico studies of Shewanella metabolism. The developed models provide a platform for a systematic investigation of Shewanella metabolism to aid researchers using Shewanella in various biotechnology applications.